Clarifying the Optimal Application of SLT Therapy Trial

Description

The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.

Conditions

Glaucoma and Ocular Hypertension

Study Overview

Study Details

Study overview

The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.

Clarifying the Optimal Application of SLT Therapy Trial

Clarifying the Optimal Application of SLT Therapy Trial

Condition
Glaucoma and Ocular Hypertension
Intervention / Treatment

-

Contacts and Locations

Laguna Hills

Harvard Eye Associates, Laguna Hills, California, United States, 92653

Pasadena

Doheny Eye Center UCLA, Pasadena, California, United States, 91105

Sacramento

University of California, Davis, Sacramento, California, United States, 95817

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94158

Sheridan

Mile High Eye Institute, Sheridan, Colorado, United States, 80110

Lakeworth

Clear Vue Laser Eye Center, Lakeworth, Florida, United States, 33467

Chicago

Northwestern Medical Group, Chicago, Illinois, United States, 60615

Orland Park

Arbors Centers for Eye Care, Orland Park, Illinois, United States, 60467

Peoria

Illinois Eye Center, Peoria, Illinois, United States, 61615

Baltimore

Wilmer Eye Institute Johns Hopkins, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age 18 or older and in good health
  • 2. Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes):
  • 1. High-risk ocular hypertension (OHT): IOP \> 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of \>0.2 between eyes)
  • 2. Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° \<15 dB (see figure on next page)
  • 3. Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points \<15 dB or mean deviation -12.0 dB or better with 1 central 5° points \<15 dB (see figure on next page).
  • 3. Each eye with BCVA 20/200 (UK 6/60) or better
  • 1. Use of topical IOP-lowering medications for more than 6 cumulative months at any time in the past 5 years
  • 2. Any history of IOP-lowering laser (prophylactic iridotomy not included) or surgical procedure
  • 3. Advanced POAG in either eye (worse than moderate POAG as defined above)
  • 4. Glaucoma other than POAG (including pigmentary and pseudoexfoliation glaucoma) in either eye
  • 5. Mean IOP \> 35 mmHg at either the screening or baseline visit in either eye
  • 6. Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye
  • 7. Contraindications to SLT or any other study intervention
  • 8. Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye
  • 9. Any intraocular surgical procedure within the past 6 months in either eye
  • 10. Inability to attend all scheduled study visits
  • 11. Pregnant or planning to become pregnant in the next 4 years

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

West Virginia University,

Tony Realini, MD, MPH, STUDY_CHAIR, West Virginia University

Goundappa K Balasubramani, PhD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Stephen Wisniewski, PhD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

2027-08-31